This protocol addresses subacute cutaneous lupus erythematosus (SCLE) in patients presenting with localized cutaneous lupus erythematosus skin lesions — a defined subpopulation where the extent and distribution of disease shape the treatment strategy.
In localized cutaneous lupus erythematosus, topical corticosteroids represent the mainstay of management and are effective across CLE subtypes. When localized disease warrants escalation beyond topical therapy, the protocol specifies the appropriate next steps.
The protocol involves a systemic immunosuppressant used in combination with antimalarials. The complete regimen — including the specific agent, how it is administered, and the full clinical algorithm — is available in the structured protocol below.
Topical corticosteroids are the mainstay in the treatment of localized CLE being effective in all subtypes (Figure 1), but only few controlled studies have been published proving their efficacy.
We recommend MTX up to 20 mg per week as a second-line treatment, primarily in SCLE patients, preferably subcutaneously and in addition to antimalarials.
View source ↗